Phase II Study of UCN-01 in Combination With Fluorouracil in Advanced Pancreatic Cancer
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed adenocarcinoma of the pancreas
- Progressive disease after gemcitabine-based chemotherapy for metastatic disease
- At least 1 unidimensionally measurable metastatic lesion
- At least 20 mm by conventional techniques OR
- At least 10 mm by spiral CT scan
- Primary disease site is not considered a measurable lesion
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1 OR
- Karnofsky 70-100%
Life expectancy
- More than 8 weeks
Hematopoietic
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin normal
- AST/ALT no greater than 2.5 times upper limit of normal
Renal
- Creatinine normal OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac tachyarrhythmia
Pulmonary
- No symptomatic chronic obstructive pulmonary disease
- No pulmonary embolism within the past 6 months
Other
- No prior allergic reactions to compounds of similar chemical or biological
composition to UCN-01 or other agents used in this study
- No diabetes mellitus uncontrolled by insulin or oral hypoglycemic agents
- No uncontrolled concurrent illness
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception before, during, and for 3 months
after study
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
and recovered
- No more than 1 prior chemotherapy regimen for metastatic or recurrent disease
- No prior fluorouracil in the adjuvant or inoperable, locally advanced setting (except
as a radiosensitizer)
- No other concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy and recovered
- No prior mediastinal irradiation
- No concurrent radiotherapy
Surgery
- Not specified
Other
- No prior UCN-01 or other cyclin-dependent kinase inhibitors
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational or commercial anticancer agents or therapies
- No concurrent anticonvulsant medications